Date: 2016-11-07
Type of information: Nomination
Compound:
Company: Neon Therapeutics (USA - MA)
Therapeutic area: Cancer - Oncology
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On November 7, 2016, Neon Therapeutics announced the appointment of Richard Gaynor to president of
research and development. Dr. Gaynor succeeds interim chief scientific officer Robert Tepper, M.D., a partner at Third Rock Ventures, who is continuing as a member of the company’s board of directors.
Dr. Gaynor recently retired from Eli Lilly’s oncology division, where he held the position of senior vice president of global product development and medical affairs since 2013.
Over the past 15 years he held related senior roles at Lilly Oncology, where he led preclinical and early clinical research, directed the biomarker and research group and served on key company portfolio review committees. Dr. Gaynor began his career in academia, spending nine years on the faculty at UCLA School of Medicine followed by 11 years on the faculty at UT Southwestern Medical School, including time serving as the chief of hematology-oncology and director of the
Simmons Cancer Center. In 2002, Dr. Gaynor moved to Eli Lilly where he began his industry career overseeing both oncology drug discovery and early clinical development.
Dr. Gaynor chaired the Lilly Oncology Research and Development Committee and helped oversee a variety of collaborations, including with Bristol-Myers Squibb, Merck,
AstraZeneca and GE. He is the author of nearly 150 publications and participates on numerous boards and committees, including several with the AACR, the Stand Up To Cancer scientific advisory committee, the MD Anderson Moon Shots advisory board, the Damon Runyon Cancer Research Foundation and Accelerating Cancer Cures.
Financial terms:
Latest news:
Is general: Yes
